News 2023-06-23
Porton Pharma Solutions Launches State-of-the-Art Small Molecule Platform in Shanghai, Elevating CDMO Services
We are thrilled to announce the establishment of our state-of-the-art Small Molecule Platform in Shanghai, revolutionizing our CDMO services. With this exciting development, Porton Pharma Solutions Ltd. now have seven R&D and production facilities in Shanghai that are equipped to provide comprehensive solutions for drug substance, drug preparation, synthetic macromolecules, and biological macromolecules.
As a trusted partner in the pharmaceutical industry, we understand the evolving needs of our clients and the importance of seamless integration throughout the drug development process. With our Small Molecule Platform, we offer a one-stop-shop solution, combining our expertise, cutting-edge facilities, and advanced technologies to accelerate and streamline the development of small molecule-based therapeutics.
This groundbreaking development reinforces our commitment to be at the forefront of CDMO services and empower our clients with the tools and expertise needed to succeed in the fast-paced pharmaceutical landscape. We are excited to collaborate with innovators, researchers, and pharmaceutical companies to drive scientific advancements, improve patient outcomes, and shape the future of healthcare.
Others
More
News 2026-09-17
Porton Congratulates Partner Acepodia on FDA and NMPA IND Approvals for ACE723, a Dual-Payload ADC
This project demonstrates Porton's process-development and scale-up capabilities for complex conjugates and adds to its experience supporting innovative biopharma companies worldwide.
News 2026-09-15
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.
